此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study Evaluating the Antipyretic Efficacy and Safety of an Acetaminophen/Naproxen Sodium Fixed Combination in Subjects With Endotoxin-Induced Fever

2026年11月17日 更新者:Kenvue Brands LLC

A Randomized, Single-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Antipyretic Efficacy and Safety of an Acetaminophen/Naproxen Sodium Fixed Combination in Subjects With Endotoxin-Induced Fever

To evaluate the antipyretic efficacy of a single dose of a fixed combination of acetaminophen/naproxen sodium, compared with placebo.

研究概览

详细说明

This will be a randomized, single-dose, double-blind, placebo-controlled, parallel-group study to evaluate the antipyretic efficacy and safety of a fixed-dose combination (FDC) of acetaminophen/naproxen sodium in adult subjects with endotoxin-induced fever, compared to placebo.

The study will be conducted in two study phases (Phase A and Phase B), with the intent of Phase A being for endotoxin dose evaluation and the intent of Phase B being to evaluate the investigational product (IP)/placebo.

Subjects enrolled in Phase A will not be included in Phase B, nor will data from these subjects be included in the statistical analysis. Phase A will be completed prior to starting Phase B. Data from Phase A will be reviewed by the Phase A Data Review Team to determine if a satisfactory endotoxin dosing regimen has been achieved. Once a satisfactory dosing regimen is determined, separate subjects will be enrolled in Phase B. Once the endotoxin induced qualifying fever (temperature ≥38.1°C) is established, eligible subjects will be randomized in a 1:1 allocation to receive a single dose of either the IP or the placebo

研究类型

介入性

注册 (估计的)

292

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Tennessee
      • Knoxville、Tennessee、美国、37920
        • 招聘中
        • AMR Clinical - Knoxville Tennessee
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 55年 (成人)

接受健康志愿者

是的

有资格学习的性别

男性

描述

Inclusion Criteria

Subjects must meet all of the following inclusion criteria in Sections A and B to be eligible for enrollment into the study:

A) Assessed at Screening Visit (Visit 1):

  1. Has a body mass index (BMI) of 17.5 to 37.0 (inclusive) for subjects who are 18 to 40 years old or a BMI of 17.5 to 35.0 (inclusive) for subjects who are 41 to 55 years old.
  2. Healthy, defined as having no clinically relevant abnormalities or medical conditions identified by a detailed medical history; full physical examination; blood pressure, respiratory rate, and heart rate measurements; 12-lead ECG; and clinical laboratory tests conducted at Visit 1.
  3. Has abstained from all food and drink except water at least 4 hours prior to the clinical laboratory tests at Visit 1.
  4. Has a negative QuantiFERON-TB Gold Plus tuberculosis, hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) test based on clinical laboratory tests at Visit 1.
  5. Has a negative urine drug screening test and a negative breath alcohol test conducted at Visit 1.
  6. Has adequate veins, as determined by visual inspection at Visit 1, for IV catheter insertion.
  7. Is able to comprehend the requirements of the study (based upon clinical site personnel's assessment) and is willing and able to comply with scheduled visits, procedures, and subject responsibilities specified within the informed consent form (ICF).
  8. Has provided written informed consent before participating in any study specific procedures.
  9. Agrees to follow contraception requirements (as defined in the protocol/ICF) for the duration of the study and for at least 30 days after study completion.
  10. Is a non-tobacco/nicotine user or previous user who completely stopped smoking/using any form of tobacco or nicotine-containing product at least 6 months before Visit 1.

B) Assessed at Day 0 and Day 1 (of Visit 2):

  1. Healthy, defined as having no clinically relevant abnormalities or medical conditions identified by a detailed medical history; full physical examination conducted on Day 0 (and symptoms-driven physical exam on Day 1, if applicable); blood pressure, respiratory rate, and heart rate measurements (conducted on Day 0 and Day 1); 12-lead ECG (conducted on Day 1), and clinical laboratory tests (conducted on Day 0).
  2. Has abstained from all food and drink except water at least 4 hours prior to the clinical laboratory tests on Day 0.
  3. Has a negative* urine drug screening test and a negative breath alcohol test conducted on Day 0 (*including a negative result for THC. A positive urine drug screening test for medications that have been prescribed to the subject are acceptable).
  4. Has adequate veins, as determined by visual inspection on Day 0, for IV catheter insertion.
  5. Has an oral temperature between 36.37 °C and 37.21 °C as measured on Day 0 and Day 1. If the subject's oral temperature is not between 36.37 °C and 37.21 °C after a single reading, then 2 additional oral temperature readings will be obtained within a 30-minute period. The average of these 3 consecutive temperature readings must be between 36.37 °C and 37.21 °C, with the highest value within 0.1 °C of the lowest temperature value.
  6. Agrees to follow contraception requirements (as defined in the protocol/ICF) for the duration of the study and for at least 30 days after study completion.

C) Assessed Once Qualifying Fever Established (Randomization Criteria; Phase B Only) Subjects must meet all of the following criteria following endotoxin administration in order to be randomized during Phase B. Subjects who do not meet these criteria will not be randomized.

  1. Has not experienced an allergic reaction or exaggerated systemic response to administration of endotoxin, as determined by the PI or medically qualified designee.
  2. Has not required medical management of an AE that includes an antipyretic treatment.
  3. Has developed an oral temperature of at least 38.1 ºC after endotoxin dosed per study guidelines.

Exclusion Criteria (to be assessed at Visit 1, Day 0 of Visit 2, and Day 1 of Visit 2).

Subjects must not meet any of the following exclusion criteria to be eligible for enrollment into the study

  1. Has a pregnant or nursing partner or a partner who is currently trying to become pregnant.
  2. Is self-reported to be unable to swallow whole large tablets or capsules.
  3. Has participated in any interventional clinical studies within 30 days before Visit 1.
  4. Is related to the persons involved directly or indirectly with the conduct of this study (PI, Sub-Investigator(s), study coordinators, other site personnel, employees/contractors of Kenvue or its subsidiaries, employees of IQVIA) at Visit 1.
  5. Has a known allergy or hypersensitivity to acetaminophen, naproxen, naproxen sodium, ibuprofen, other nonsteroidal anti-inflammatory drugs (NSAIDs) (including acetylsalicylic acid or other salicylates), any of the inactive ingredients in the products, ondansetron, or the endotoxin used in the study.
  6. Has a history of chronic tranquilizer use, heavy drinking, or substance abuse, as judged by the PI or designee, in the last five years.
  7. To be assessed at Day 0: Has consumed alcohol within 48 hours prior to Day 0.
  8. To be assessed at Day 0: Has consumed caffeine or other methylxanthine containing products (e.g., chocolate bars or chocolate beverages, coffee, tea, cola, or caffeinated energy drinks) within 24 hours prior to Day 0.
  9. To be assessed at Day 0: Has experienced cold/flu symptoms (i.e., runny nose, cough, pain, and/or fever) within 2 weeks prior to Day 0.
  10. To be assessed at Day 0: Has used prescription or nonprescription drugs within 5 half-lives prior to Day 0.
  11. To be assessed at Day 0: Has used any drug that may impact gastric motility, such as glucagon-like peptide-1 (GLP-1) medication, within 35 days prior to Day 0.
  12. To be assessed at Day 0: Has used vitamins or dietary/herbal supplements within 7 days prior to Day 0.
  13. Routinely uses oral analgesics ≥ 5 times per week.
  14. Has any disease or condition that may cause abnormal alterations in body temperature.
  15. Has a clotting/bleeding disorder and is at risk of excessive bleeding.
  16. Has evidence or history of a clinically significant laboratory abnormality or hematological, renal, endocrine, pulmonary, cardiovascular, hepatic, psychiatric, neurologic, immunologic, or allergic disease (excluding untreated, asymptomatic, seasonal allergies at the time of dosing) within the last 5 years that, in the PI's or medically qualified designee's opinion, may jeopardize the subject's safety or well-being or the integrity of the study.
  17. Has any clinically significant gastrointestinal disorder/disease/condition or is taking medication for any such disorder/disease/condition that, per the PI's or medically qualified designee's judgement, could affect the absorption, metabolism, or excretion of the study medication.
  18. Has a history of recurrent, acute, or chronic infections of any type or any findings suggestive of occult infection, such as tuberculosis, sinusitis, urinary tract infection, respiratory tract or dental (abscess) infection, etc. Also excluded are subjects with frequent (more than 3 outbreaks per year), recurrent oral or genital herpes, recurrent herpes zoster, or any infection otherwise judged by the PI or medically qualified designee to have the potential for exacerbation by participation in the study.
  19. Heart rate < 50 bpm or is deemed to be at high risk of syncope and/or hypotension per the clinical judgment of the PI or medically qualified designee at Visit 1, on Day 0, or on Day 1.
  20. Supine blood pressure <90 or >140 mmHg (systolic) or <50 or >90 mmHg (diastolic), following at least 5 minutes of supine rest, as assessed at Visit 1, on Day 0, or on Day 1.
  21. Supine 12-lead ECG demonstrating QTcF >450 msec or a QRS interval >120 msec at Visit 1 or on Day 1 prior to endotoxinadministration.
  22. Other severe, acute or chronic medical or psychiatric condition(s) or laboratory abnormality(ies) that may increase the risk associated with study participation or ISM administration or may interfere with the interpretation of study results.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Acetaminophen 650 mg/Naproxen Sodium 220 mg

Acetaminophen 650 mg/Naproxen Sodium 220 mg (administered as two tablets of Acetaminophen/Naproxen Sodium 325 mg/110 mg).

The IP is to be taken as a single dose (administered as two tablets of Acetaminophen/Naproxen Sodium 325 mg/110 mg) orally with 180 mL of room temperature water.

安慰剂比较:Placebo

Placebo (administered as two tablets of placebo).

The placebo is to be taken as a single dose (administered as two tablets of placebo) orally with 180 mL of room temperature water.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Time-weighted Sum of Temperature Differences (WSTD) from 0 to 8 hours (WSTD 0-8)
大体时间:Baseline (0 hour) up to 8 hours

WSTD 0-8 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110,120,150,180,210,240,270,300,330,360,390,420,450, and 480 minutes after the investigational study material (ISM) administration (Hour 0). Temperature difference was defined as baseline temperature (at Hour 0) minus the post-baseline temperature at each time point up to 8 hours (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110 minutes,2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours).

Baseline (0 hour) up to 8 hours
Time-weighted Sum of Temperature Differences (WSTD) from 0 to 12 hours (WSTD 0-12)
大体时间:Baseline (0 hour) up to 12 hours

WSTD 0-12 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80,90,100,110,120,150,180,210,240,270,300,330,360,390,420,450, 480,510,540,570,600,630,660,690,and 720 minutes after the investigational study material (ISM) administration (Hour 0). Temperature difference was defined as baseline temperature (at Hour 0) minus the post-baseline temperature at each time point up to 12 hours (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110 minutes,2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5 , and 12 hours).

Baseline (0 hour) up to 12 hours

次要结果测量

结果测量
措施说明
大体时间
Time-weighted Sum of Temperature Differences (WSTD) from 0 to 6 hours (WSTD 0-6)
大体时间:Baseline (0 hour) up to 6 hours

WSTD 0-6 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110,120,150,180,210,240,270,300,330, and 360 minutes after the investigational study material (ISM) administration (Hour 0). Temperature difference was defined as baseline temperature (at Hour 0) minus the post-baseline temperature at each time point up to 6 hours (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110 minutes,2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, and 6 hours).

Baseline (0 hour) up to 6 hours
Time-weighted Sum of Temperature Differences (WSTD) from 0 to 10 hours (WSTD 0-10)
大体时间:Baseline (0 hour) up to 10 hours

WSTD 0-10 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80,90,100,110,120,150,180,210,240,270,300,330,360,390,420,450, 480,510,540,570, and 600 minutes after the investigational study material (ISM) administration (Hour 0). Temperature difference was defined as baseline temperature (at Hour 0) minus the post-baseline temperature at each time point up to 10 hours (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110 minutes,2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, and 10 hours).

Baseline (0 hour) up to 10 hours
Subject Global Evaluation Questionnaire
大体时间:Visit 2 - 12 hours prior to first use of rescue medication, or at time of early discontinuation (whichever occurs first).

Participants will be asked to evaluate the performance of the investigational study material (ISM) using a 5-point Likert scale : 0= poor , 1=fair , 2=good , 3=very good , 4=excellent

Visit 2 - 12 hours prior to first use of rescue medication, or at time of early discontinuation (whichever occurs first).
Time to first use of rescue medication
大体时间:Baseline (0 hour) to 12 hours

Time to rescue medication (other than study treatment) was defined as time from first dosing of study medication to the time a participant first takes a rescue medication, or to the end of the study time for participants that do not take any rescue medication prior to the end of the study. The rescue medication was defined as medication received for the treatment of fever during the time period from the administration of study medication to the time of end of the study.

Baseline (0 hour) to 12 hours
Proportion of subjects using rescue medication from 0 to 12 hours
大体时间:Baseline (0 hour) to 12 hours
Baseline (0 hour) to 12 hours

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Tobore Tobore、Kenvue Brands LLC

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年10月20日

初级完成 (估计的)

2027年10月29日

研究完成 (估计的)

2027年10月29日

研究注册日期

首次提交

2026年10月15日

首先提交符合 QC 标准的

2026年11月17日

首次发布 (实际的)

2026年11月19日

研究记录更新

最后更新发布 (实际的)

2026年11月19日

上次提交的符合 QC 标准的更新

2026年11月17日

最后验证

2026年11月11日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅